LaunXP will pay Apollomics $10m upfront within 60 days of the agreement date. Apollomics is also qualified for potential ...

BMY obtains CHMP recommendation for Opdivo for perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by ...

C4 Therapeutics, Inc.’s CCCC share price has dipped by 10.31%, which has investors questioning if this is right time to buy.

Colorectal cancer is a serious but preventable disease if detected early. Advances in diagnostics, such as biomarker analysis ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Nuvalent, Inc. (NASDAQ:NUVL – Get Free Report) has been assigned an average rating of “Moderate Buy” from the eleven ratings ...

The evolution of genomic medicine is driving personalized healthcare, integrating AI and sequencing technologies for improved ...

PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel ...

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but ...

A study in mice reveals key interactions between proteins involved in fibroblast growth factor signaling and how they contribute to distinct stages of eye lens development.

The FDA has approved Egrifta WR, a concentrated formulation (F8) of tesamorelin, for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.